Given that the alpelisib-fulvestrant combination is a clinical standard for ER+/HER2- breast cancer[50], our results suggest that patients with high FGFR1 expression might benefit from this modified regimen, thereby enhancing clinical outcomes in resistant cases. This evidence concerns the gene ESR1 and breast carcinoma.